Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Announces Wide-Ranging List of Compounding Priorities for 2019

Executive Summary

FDA has announced a multifaceted effort to tackle the oversight of drug compounding facilities this year. On the to do list: setting the groundwork for establishing centers for excellence for outsourcing facilities; finalizing a guidance on identifying insanitary conditions at drug compounding facilities, and finalizing a memorandum of understanding targeting traditional compounders that distribute an “inordinate” amount of their compounded drugs across state lines.

You may also be interested in...



US FDA Contracting Update: From Rating Site Quality Maturity To Blocking COVID-19 Scams

Contracts in works also would help track APIs, promote gene therapy standards, improve drug compounding, help extend shelf lives for US stockpile products and improve budget execution.

NASEM Report Urges Tougher Oversight of 503A Pharmacies That Compound Topical Pain Creams

There is scant evidence to support use of compounded topical pain creams, and tougher controls are needed to regulate 503A pharmacies, according to a recent study by the National Academies.

The FDA Aims To Strike Balance On Inspecting Physicians Who Compound Drugs

Just how much will the FDA look the other way when it comes to inspecting physician compounders?

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS125047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel